CGS 27023A

CDG 27023A

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

MacPherson LJ, Bayburt EK, Capparelli MP, et al. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem 1997 Aug 1; 40: 2525–32
Article PubMed CAS Google Scholar
Levitt NC, Eskens F, Propper DJ, et al. A phase one pharmacokinetic study of CGS27023A, a matrix metalloproteinase inhibitor. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 16–19; Los Angeles. Proc Soc Clin Oncol 1998; 17: 213
Google Scholar
Wood JM, Müller M, Schnell C, et al. CGS 27023A, a potent and orally active matrix metalloprotease inhibitor with antitumor activity. 89th Annual Meeting of the American Association for Cancer Research 1998 Mar 28–Apr 1; New Orleans. Philadelphia: American Association for Cancer Research, 1998: 83
Google Scholar
O’Byrne EM, Parker DT, Roberts ED, et al. Oral administration of a matrix metalloproteinase inhibitor, CGS 27023A, protects the cartilage proteoglycan matrix in a partial meniscectomy model of osteoarthritis in rabbits. Inflamm Res 1995 Aug; 44 Suppl. 2: 117–8
Article Google Scholar

CGS 27023A. Drugs R&D 1, 144–145 (1999). https://doi.org/10.2165/00126839-199901020-00007

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.